The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
News|Articles|June 9, 2026
FDA Flashback: Breast Cancer Decisions and News From May 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.
Advertisement
Advertisement
Catch a glimpse of the breast cancer–related FDA decisions granted in May 2026, including several drug approvals and an updated Prescription Drug User Fee Act (PDUFA) target action date.
Related to this article
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement